Welcome to our dedicated page for Veracyte news (Ticker: VCYT), a resource for investors and traders seeking the latest updates and insights on Veracyte stock.
Veracyte, Inc. reports developments in cancer diagnostics, with recurring updates centered on its Veracyte Diagnostics Platform and genomic tests used in prostate, thyroid, bladder, and breast cancer. Company news frequently covers Decipher Prostate, Decipher Bladder, Afirma, Prosigna, and development work in whole-genome minimal residual disease and multi-omics applications.
Veracyte updates commonly include quarterly financial results, testing revenue and volume trends, clinical evidence presented at oncology and urology meetings, real-world data analyses, product-development capabilities, and leadership roles tied to assay development, software, bioinformatics, and AI-enabled diagnostics.
Veracyte (Nasdaq: VCYT) named Kevin Haas, Ph.D., as Chief Development and Technology Officer, effective March 24, 2026. The newly created role will oversee end-to-end product development across assays, software, bioinformatics, and the product development program office to support MRD and multi-omics initiatives.
Dr. Haas brings more than 15 years of life sciences experience, including senior technology and bioinformatics leadership roles at Myriad and Counsyl, and holds a Ph.D. in chemical engineering from UC Berkeley.
Veracyte (Nasdaq: VCYT) reported strong fourth-quarter and full-year 2025 results: Q4 total revenue $140.6M (+19%), testing revenue $135.8M (+21%), and full-year revenue $517.1M (+16%).
GAAP net income was $41.1M for Q4 and $66.4M for 2025; cash from operations was $52.6M in Q4 and $136.3M for the year. The company reiterates 2026 revenue guidance of 10–13% ($570M–$582M) and expects adjusted EBITDA margin of ~25%.
Veracyte (Nasdaq: VCYT) will present more than 15 abstracts at the 2026 ASCO Genitourinary Cancers Symposium, Feb 26–28 in San Francisco, highlighting Decipher Prostate and Bladder tests and the upcoming TrueMRD™ MIBC test.
Presentations include SURE‑02 phase II results, HCRN GU 20-444 oral data, and multiple real-world Decipher and GRID analyses supporting clinical decision-making in urologic cancers.
Veracyte (Nasdaq: VCYT) will present at two investor conferences in March 2026: a presentation at the Raymond James Institutional Investors Conference in Orlando on March 3, 2026 at 8:05 AM ET, and a fireside chat at the Leerink Partners Global Health Conference in Miami on March 9, 2026 at 10:40 AM ET.
Live audio webcasts will be available via the company investor website, with replays accessible for 90 days after each live broadcast.
Veracyte (Nasdaq: VCYT) will release fourth-quarter and full-year 2025 financial results after market close on Wednesday, February 25, 2026. Management will host a conference call and webcast at 4:30 p.m. ET the same day to discuss results and provide a general business update.
The live webcast and replay will be available on the company website, and dial-in details require registration via the company-provided links.
Veracyte (Nasdaq: VCYT) reported preliminary, unaudited results for Q4 and full-year 2025. Key highlights: Q4 total revenue $138M–$140M (+16%–18%); FY2025 total revenue $515M–$517M (+~16%); FY testing revenue $491M–$493M (+17%–18%); FY testing volume ~169,700 (+19%). Decipher volume ~102,000 (+27%) and Afirma volume ~67,700 (+11%). Veracyte expects adjusted EBITDA margin >25% for 2025 and issues 2026 guidance of $570M–$582M (10%–13% growth) with testing revenue guidance of $559M–$569M (14%–16%).
Veracyte (Nasdaq: VCYT) will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026 at 9:45 a.m. PT. Management's live audio webcast will be available at the company's investor website, and a replay will be accessible for 30 days after the live broadcast.
Investors can listen via the investor events page at http://investor.veracyte.com/events-presentations.
Veracyte (Nasdaq: VCYT) will participate in three investor conferences in November 2025 with scheduled fireside chats and live webcasts.
- Wolfe Research Healthcare Conference — New York: Fireside chat on November 17, 2025 at 10:00 a.m. ET
- Jefferies Global Healthcare Conference — London: Fireside chat on November 20, 2025 at 11:30 a.m. GMT
- Stephens Annual Investment Conference — Nashville: Fireside chat on November 20, 2025 at 11:00 a.m. CT
Live audio webcasts will be available at http://investor.veracyte.com/events-presentations, and replays will be accessible for 90 days after each live broadcast.
Veracyte (Nasdaq: VCYT) reported Q3 2025 results with total revenue of $131.9M (up 14%) and testing revenue of $127.8M (up 17%). Testing volume rose 19% to 43,679 tests; total volume rose 18% to 45,888 tests. GAAP net income was $19.1M (15% of revenue) and adjusted EBITDA was $39.7M or 30.1% of revenue. Cash, cash equivalents and short-term investments totaled $366.4M at quarter end, with cash from operations of $44.8M in the quarter.
The company raised full-year 2025 guidance to testing revenue $484M–$487M and total revenue $506M–$510M, and raised adjusted EBITDA margin guidance to over 25%. Key product and clinical milestones and launches were also highlighted.
Veracyte (NASDAQ: VCYT) announced two publications (Nov 3, 2025) showing research use of the Afirma GRID whole-transcriptome tool to derive mRNA signatures that may preoperatively stratify thyroid nodule cancer risk.
Key findings: researchers analyzed 445 Afirma GSC-tested samples and screened 30 molecular signatures; an "invasion signature" associated with a 30% greater likelihood of intermediate/high-risk cancer, while a "NIS expression" signature predicted low-risk cancers. Authors say further validation is required before clinical use.